# Senseonics

Eversense E3 — Fluorescent optical sensor, 180-day implant.

Source: https://en.bioecon.ru/companies/senseonics/
Updated: 2026-07-02

- Country: United States

## Verifiable facts

| Fact | Value | Source |
| --- | --- | --- |
| Capacity | The company believes contract manufacturers have sufficient capacity to meet requirements | https://materials.proxyvote.com/Approved/81727U/20260326/10K_629522.PDF |
| Certification | Received certification from BSI, a Notified Body to the International Standards Organization | https://materials.proxyvote.com/Approved/81727U/20260326/10K_629522.PDF |
| Regulatory approval | Eversense E3 approved by FDA (180-day) and received CE Mark (6-month). Eversense 365 approved by FDA and CE Mark. | https://diatribe.org/diabetes-technology/180-day-implantable-cgm-eversense-e3-approved-fda, https://www.fda.gov/medical-devices/recently-approved-devices/eversense-e3-continuous-glucose-monitoring-cgm-system-p160048s021, https://www.senseonics.com/investor-relations/news-releases/2022/06-16-2022-113017038, https://www.senseonics.com/investor-relations/news-releases/2024/09-17-2024-120118174, https://www.senseonics.com/investor-relations/news-releases/2026/03-02-2026-210131962 |
| Production site | Manufacturing is outsourced to contract manufacturers across North America and Europe. | https://materials.proxyvote.com/Approved/81727U/20260326/10K_629522.PDF |
| Revenue | Full year 2025 revenue of $35.3 million | https://www.senseonics.com/investor-relations/news-releases/2026/03-02-2026-210131962 |

Independent sources: diatribe.org, fda.gov, materials.proxyvote.com

## Technologies

- [Implantable biosensors for chronic disease](https://en.bioecon.ru/technology/implantable-biosensors-chronic-disease/)
- [Wearable biodiagnostics](https://en.bioecon.ru/technology/wearable-biodiagnostics/)